

ASH 2020 Abstracts
Janssen Newsroom

janssen | PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Abstract No.	Title	Date / Time (ET)
Ciltacabtagene Autoleucel (cilta-cel, JNJ-4528)		
	Oral Presentation	
Abstract #177	CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma (RRMM)	Saturday, December 5 3:00 p.m.
	Poster Presentations	
Abstract #1412	Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in RRMM	Saturday, December 5 10:00 a.m. – 6:30 p.m.
Abstract #2291	Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for RRMM	Sunday, December 6 10:00 a.m. – 6:30 p.m.
Abstract #3240	Cytokine Release Syndrome in Patients With RRMM Treated With Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study	Monday, December 7 10:00 a.m. – 6:30 p.m.
DARZALEX® (daratumumab)		
	Oral Presentations	
Abstract #412	APOLLO: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with RRMM	Sunday, December 6 3:00 p.m.
Abstract #549	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 12 Months of Maintenance Therapy	Monday, December 7 10:15 a.m.
Abstract #552	Reduction in Absolute Involved Free Light Chain and Difference Between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone With or Without Daratumumab: Results From ANDROMEDA	Monday, December 7 11:15 a.m.

Abstract No.	Title	Date / Time (ET)
DARZALEX® (daratumumab) continued		
	Poster Presentations	
Abstract #1392	Outcomes by Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from ANDROMEDA	Saturday, December 5 10:00 a.m. – 6:30 p.m.
Abstract #1640	Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone: Results from the Phase 3 ANDROMEDA Study	Saturday, December 5 10:00 a.m. – 6:30 p.m.
Abstract #1380	Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma Across Lines of Therapy in the Phase 2 PLEIADES Study: Initial Results of the DARA SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the DARA SC Plus Bortezomib/ Melphalan/Prednisone (D-VMP) and DARA SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts	Saturday, December 5 10:00 a.m. – 6:30 p.m.
Abstract #1409	Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 ANDROMEDA Study	Saturday, December 5 10:00 a.m. – 6:30 p.m.
Abstract #2305	Rapid and Deep Hematologic Responses are Associated With Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results From ANDROMEDA	Sunday, December 6 10:00 a.m. – 6:30 p.m.
Abstract #2276	Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-ineligible NDMM: the Phase 3 MAIA Study	Sunday, December 6 10:00 a.m. – 6:30 p.m.
Abstract #2290	Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in RRMM: Pooled Subgroup Analysis of LEPUS and CASTOR	Sunday, December 6 10:00 a.m. – 6:30 p.m.
Abstract #2317	Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-ineligible (TIE) NDMM Patients (Pts) Treated with Daratumumab-based Regimens: Analysis of MAIA and ALCYONE	Sunday, December 6 10:00 a.m. – 6:30 p.m.

Abstract No.	Title	Date / Time (ET)
DARZALEX® (daratumumab) continued		
	Poster Presentations	
Abstract #3209	Predictive Markers of High-Grade or Serious Treatment-emergent Infections with Daratumumab-based Regimens in NDMM	Monday, December 7 10:00 a.m. – 6:30 p.m.
Abstract #3238	Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status For Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab in ALCYONE	Monday, December 7 10:00 a.m. – 6:30 p.m.
Abstract #3243	A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with RRMM	Saturday, December 5 5:00 p.m.
Talquetamab		
	Oral Presentation	
Abstract #290	A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with RRMM	Saturday, December 5 5:00 p.m.
Teclistamab		
	Oral Presentation	
Abstract #180	Updated Phase 1 Results of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in RRMM	Saturday, December 5 3:45 p.m.
	Poster Presentation	
Abstract #3194	Translational approach of using ex vivo cytotoxicity and early clinical data to predict teclistamab efficacious therapeutic range in multiple myeloma patients	Monday, December 7 10:00 a.m. – 6:30 p.m

Abstract No.	Title	Date / Time (ET)
IMBRUVICA® (ibrutinib)		
	Oral Presentations	
Abstract #123	Ibrutinib plus venetoclax for firstline treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study.	Saturday, December 5 12:30 p.m.
Abstract #TBD	Real-world prognostic biomarker testing, treatment patterns and dosing among 1461 patients (pts) with CLL/SLL from the informCLL™ prospective observational registry.	Saturday, December 5 TBD
Abstract #336	Five-year follow-up of ibrutinib plus rituximab vs placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase 3 iNNOVATE™ study.	Sunday, December 6 12:30 p.m.
Abstract #372	Clinical outcomes among real-world patients with CLL initiating firstline ibrutinib or chemoimmunotherapy stratified by risk status: results from a US retrospective chart review study.	Sunday, December 6 1:00 p.m.
	Poster Presentations	
Abstract #2220	Outcomes of firstline ibrutinib in patients with CLL/SLL and high-risk genomic features with up to 6.5 years follow-up: integrated analysis of two phase 3 studies (RESONATE-2 and iLLUMINATE).	Sunday December 6 10:00 a.m. – 6:30 p.m
Abstract #2219	Long-term efficacy of firstline ibrutinib treatment for CLL with 4 years of follow-up in patients with TP53 aberrations (del(17p) or TP53 mutation): a pooled analysis from 4 clinical trials.	Sunday, December 6 10:00 a.m. – 6:30 p.m
Abstract #2938	Ibrutinib plus venetoclax in patients with relapsed/refractory mantle cell lymphoma: results from the safety run-in period of the phase 3 SYMPATICO study.	Monday, December 7 10:00 a.m. – 6:30 p.m.
Abstract #2937	Long-term follow-up of ibrutinib treatment for rituximab-refractory Waldenström's macroglobulinemia: final analysis of the open-label substudy of the phase 3 iNNOVATE™ trial.	Monday, December 7 10:00 a.m. – 6:30 p.m.

Abstract No.	Title	Date / Time (ET)
IMBRUVICA® (ibrutinib) continued		
	Poster Presentations	
Abstract #TBD	Ibrutinib maintenance (I-M) following intensive induction in mantle cell lymphoma (MCL): efficacy, safety and changes in minimal residual disease.	TBD
JNJ-3093		
	Poster Presentations	
Abstract #1809	FEIBA® and NovoSeven® Neutralize the Anticoagulant Effects of a Novel Small Molecule FXIa Inhibitor BMS-986177/JNJ-70033093 in Human Plasma and Whole Blood In Vitro	Sunday, December 6 10:00 a.m. – 6:30 p.m.
Nipocalimab		
	Poster Presentations	
Abstract #TBD	Identification of a Warm Autoimmune Hemolytic Anemia (wAIHA) population using predictive analytics of a known clinically profiled cohort	TBD